Taken together, our study highlights a novel complex regulatory network that links BET proteins to both NFκB and STAT survival signaling pathways controlling both BCL2A1 and c-MYC expression in DLBCL. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.